Use of Imatinib Mesylate in Gastrointestinal Stromal Tumours: Pan-Birmingham Cancer Network Experience

Clinical Oncology

Volumn 20, Issue 7, 2008, Pages 517-522

  Wong, D W Y ^a   Lupton, S C ^a   Bhatt, L ^a   Gross, L ^b   Taniere P ^a   Peake, D R ^a   Spooner, D ^a   Geh, J I ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Gastrointestinal stromal tumours; imatinib mesylate; metastatic; small intestine; stomach; unresectable

Indexed keywords

IMATINIB; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; APPENDIX TUMOR; ARTICLE; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LIVER TOXICITY; LYMPHOMATOID GRANULOMATOSIS; MALE; MEDICAL AUDIT; NAUSEA AND VOMITING; PERIORBITAL EDEMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SMALL INTESTINE TUMOR; STOMACH TUMOR; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 48349136906     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.04.008     Document Type: Article

References (28)

1. Kindblom L.G., Remotti H.E., Aldenborg F., and Meis-Kindblom J.M. Gastrointestinal pacemaker cell tumour (GIPACT): gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152 (1998) 1259-1269
2. Lux M.L., Rubin B.P., Biase T.L., et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumours. Am J Pathol 156 (2000) 791-795
3. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumours: a consensus approach. Hum Pathol 33 (2002) 459-465
4. Nilsson B., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the pre-imatinib mesylate era. Cancer 103 (2005) 821-829
5. Reid R, Bulusu R, Buckels J, et al. Guidelines for the management of gastrointestinal stromal tumours (GISTs). Novartis Oncology. April 2006.
6. Dematteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 (2000) 51-58
7. Dematteo R.P., Heinrich M.C., El-Riffai W.M., and Dimetri G. Clinical management of gastrointestinal stromal tumours: before and after STI571. Hum Pathol 33 (2002) 466-477
8. Miettinen M., Makhlouf H., Sobin L., et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30 (2006) 477-489
9. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 471-480
10. Blanke C.D., Demetri G.D., Von Mehren M., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26 4 (2008) 620-625
11. National Institute for Health and Clinical Excellence. Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours. October 2004.
12. Blay J.Y., Bonvalot S., Casali P., et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16 (2005) 566-578
13. National Institute for Health and Clinical Excellence. Improving outcomes for people with sarcoma - Cancer Service Guidance. March 2006.
14. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
15. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
16. Miettinen M., El-Rifai W., Sobin L.H., et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 33 5 (2002) 478-483
17. O'Sullivan B., Deshmukh N., Reynolds G., et al. Retrospective analysis of GIST in one regional UK reference centre. Gut 56 (2007) A7
18. Heinrich M.C., Corless C.L., Duensing A., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
19. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42 8 (2006) 1093-1103
20. Linton K.M., Taylor M.B., and Radford J.A. Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol 79 (2006) e40-e44
21. Antoch G., Kanja J., Bauer S., et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45 3 (2004) 357-365
22. Bauer S., Hartmann J.T., and de Wit M. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117 2 (2005) 316-325
23. Hasegawa J., Kanda T., Hirota S., et al. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol 12 3 (2007) 212-217
24. Salmons N., Gregg R.J., Pallalau A., et al. Lymphomatoid granulomatosis in a patient previously diagnosed with a gastrointestinal stromal tumour and treated with imatinib. J Clin Pathol 60 (2007) 199-201
25. Zalcberg J.R., Verweij J., Casali P.G., et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41 (2005) 1751-1757
26. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
27. Heinrich M.C., Maki R.G., Corless C.L., et al. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol 24 18S (2006) 9502
28. Koon N., Schneider-Stock R., Sarlomo-Rikala M., et al. Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53 (2004) 235-240